browse Browse

pac.dog pac.dog / Lobbying

1st Quarter - Report · 2026

Filing UUID
b28e4b29-3a8f-4139-bfe8-ef7fa5f44580
Type
Q1 — 1st Quarter - Report
Period
first_quarter
Year
2026
Posted
2026-04-20 22:10:48
Income (reported)
$50,000
Expenses (reported)
Filing document
Open on lda.senate.gov
Registrant (lobbying firm)

AVENUE SOLUTIONS

Government representation

Contact
AMY TEJRAL
Phone
+1 202-347-9848
Address
zip:20004, city:Washington, state:DC, street:401 9th St. NW Suite 720
Client

GENENTECH USA, INC.

Biotechnology

State
CA
Country
US
Government-entity client
false
Effective date
2021-01-01
Issues lobbied + lobbyists (2)

MMM — Medicare/Medicaid

Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act; Issues related to Senate Finance Dear Colleague process

Lobbyists:

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

HCR — Health Issues

Issues related to 340b drug pricing program; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders and expiring Advanced Premium Tax Credits (APTC)

Lobbyists:

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.